{
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF VDAC1 is reconstituted into supported lipid bilayers with Chol/CL molar ratios ranging from 0.5 to 10, THEN AFM imaging will reveal a monotonic increase in honeycomb array area fraction (f_h) from <0.15 at Chol/CL=0.5 to >0.70 at Chol/CL=10, with a Hill-type transition midpoint at Chol/CL \u2248 2-4.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "VDAC1_density",
          "unit": "monomers/\u03bcm\u00b2",
          "low": 500.0,
          "high": 5000.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "PE_fraction",
          "unit": "mol",
          "low": 0.2,
          "high": 0.45,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "temperature",
          "unit": "\u00b0C",
          "low": 22.0,
          "high": 37.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CL_mol_percent",
          "unit": "mol%",
          "low": 2.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "Hill_coefficient",
          "unit": "dimensionless",
          "low": 1.0,
          "high": 4.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 8.0,
      "experimental_protocol": "Reconstitute purified human VDAC1 into supported lipid bilayers (POPC/POPE/CL/Chol at defined ratios) on mica via vesicle fusion. Image in fluid tapping-mode AFM (Bruker MultiMode 8) at sub-nm resolution. Quantify honeycomb lattice area fraction using autocorrelation analysis across \u226520 fields per condition, 5 Chol/CL ratios \u00d7 3 replicates. Timeline: 8-10 weeks.",
      "expected_outcome": "Sigmoidal relationship between Chol/CL and f_h; lattice spacing ~6-7 nm consistent with published honeycomb periodicity; CL titration at fixed Chol causes",
      "null_outcome": "No correlation between Chol/CL and f_h; honeycomb arrays persist at Chol/CL=0.5; or arrays never form regardless of ratio, indicating protein-protein contacts dominate over lipid environment.",
      "dose_ranges": {
        "CL": {
          "doses": [
            2.0,
            5.0,
            10.0,
            15.0,
            20.0
          ],
          "unit": "mol%;"
        },
        "Cholesterol": {
          "doses": [
            5.0,
            10.0,
            20.0,
            30.0,
            40.0
          ],
          "unit": "mol%"
        }
      },
      "readouts": [
        "AFM topography (honeycomb lattice area fraction",
        "nearest-neighbor distance",
        "defect density)",
        "laurdan generalized polarization (membrane order)",
        "DLS for vesicle QC"
      ],
      "controls": [
        "VDAC1-free bilayers (same lipid compositions)",
        "POPC-only bilayers + VDAC1",
        "heat-denatured VDAC1",
        "scrambled lipid order (rapid freeze-thaw)",
        "---",
        "##"
      ]
    },
    {
      "id": "H2",
      "prediction": "IF HK-II is displaced from VDAC1 honeycomb arrays (by glucose-6-phosphate or clotrimazole treatment), THEN within 10-30 minutes: (a) CL-specific fluorescent probe (NAO or TopFluor-CL) signal at VDAC clusters increases \u22652-fold, and (b) honeycomb array area fraction decreases by \u226540%, and (c) both effects are abolished by prior CL depletion (PLS3 knockdown or CL synthase inhibition).",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "II_displacement_rate",
          "unit": "min\u207b\u00b9",
          "low": 0.01,
          "high": 0.5,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CL_exposure_fold_change",
          "unit": "fold",
          "low": 1.0,
          "high": 5.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "f_h_decrease",
          "unit": "%",
          "low": 0.0,
          "high": 80.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "clotrimazole_EC50",
          "unit": "\u03bcM",
          "low": 1.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "G6P_concentration",
          "unit": "mM",
          "low": 0.5,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "time_to_disassembly",
          "unit": "min",
          "low": 5.0,
          "high": 60.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CL_content_threshold",
          "unit": "mol%",
          "low": 2.0,
          "high": 8.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 6.0,
      "experimental_protocol": "Use isolated rat liver mitochondria or U2OS cells expressing VDAC1-GFP. Displace HK-II with clotrimazole (5-30 \u03bcM) or G6P (2-10 mM). Monitor CL exposure via NAO fluorescence (confocal, FRET-based) and VDAC organization via STORM/PALM super-resolution or AFM on isolated OMM sheets. CL-depletion arm: pre-treat with CLS1 inhibitor or siRNA 48h prior. Timeline: 12-16 weeks.",
      "expected_outcome": "HK-II displacement causes rapid CL unmasking at VDAC sites (NAO increase), followed by honeycomb disassembly (reduced cluster size in STORM); CL-depleted mitochondria show HK-II displacement but no array disruption, proving CL is the mediating lipid.",
      "null_outcome": "HK-II displacement occurs but CL exposure does not change; or honeycomb arrays disassemble equally in CL-depleted mitochondria; or no detectable honeycomb structures exist in native OMM under any condition.",
      "dose_ranges": {
        "Clotrimazole": {
          "doses": [
            1.0,
            5.0,
            10.0,
            20.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "G6P": {
          "doses": [
            0.5,
            2.0,
            5.0,
            10.0
          ],
          "unit": "mM;"
        },
        "CLS1 siRNA": {
          "doses": [
            10.0,
            30.0
          ],
          "unit": "nM"
        }
      },
      "readouts": [
        "NAO fluorescence intensity at mitochondria (confocal)",
        "VDAC1 cluster size/density (STORM)",
        "HK-II co-IP or proximity ligation assay",
        "cytochrome c release (ELISA)",
        "\u0394\u03a8m (TMRE)"
      ],
      "controls": [
        "Vehicle-treated mitochondria",
        "HK-II-free VDAC1 (HK-II KO cells)",
        "non-displaceable HK-II mutant (VDAC1-E73Q)",
        "CL-replete vs CL-depleted matched pairs",
        "clotrimazole + exogenous CL rescue",
        "---",
        "##"
      ]
    },
    {
      "id": "H3",
      "prediction": "IF CBD (1-10 \u03bcM) is added to VDAC1-containing reconstituted bilayers, THEN honeycomb array density will change by \u226530% at concentrations below the Kd for direct VDAC binding (11 \u03bcM), AND this effect will be reproduced by a membrane-order-matched control compound (e.g., cholesterol hemisuccinate or vitamin E) that does not bind VDAC, AND will NOT be abolished by VDAC1 point mutations (e.g., E73Q, T19A) that disrupt known drug-binding pockets.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "CBD_concentration",
          "unit": "\u03bcM",
          "low": 0.1,
          "high": 30.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CBD_Kd_VDAC",
          "unit": "\u03bcM",
          "low": 5.0,
          "high": 20.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "f_h_change_at_subKd",
          "unit": "%",
          "low": 0.0,
          "high": 60.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "logP_matched_control",
          "unit": "(uniform)",
          "low": 5.0,
          "high": 7.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "partition_coefficient_OMM",
          "unit": "(log-uniform)",
          "low": 100.0,
          "high": 10000.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "Reconstitute VDAC1 (WT and E73Q, T19A mutants) into supported bilayers (OMM-mimetic: POPC/POPE/CL/Chol 48:28:10:14). Treat with CBD (0.5, 1, 3, 5, 10, 30 \u03bcM), simvastatin (1, 5, 10, 30 \u03bcM), vitamin E (logP-matched non-VDAC-binder), and cholesterol hemisuccinate. Image by AFM; measure membrane order by laurdan GP spectroscopy in parallel GUVs. Timeline: 10-14 weeks.",
      "expected_outcome": "CBD at 1-5 \u03bcM (sub-Kd) alters f_h by \u226530%; vitamin E at equi-partitioning concentration produces similar effect; VDAC binding-site mutants show identical f_h shifts as WT, confirming membrane-mediated mechanism. Laurdan GP correlates with f_h across all compounds.",
      "null_outcome": "CBD effects on f_h only appear at >Kd concentrations; VDAC binding-site mutants are resistant to CBD-induced reorganization; logP-matched non-binders have no effect; or laurdan GP changes do not correlate with array changes, indicating direct binding is necessary.",
      "dose_ranges": {
        "CBD": {
          "doses": [
            0.5,
            1.0,
            3.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "Simvastatin": {
          "doses": [
            1.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "Vitamin E": {
          "doses": [
            1.0,
            5.0,
            10.0,
            30.0
          ],
          "unit": "\u03bcM;"
        },
        "CHS": {
          "doses": [
            1.0,
            5.0,
            10.0
          ],
          "unit": "\u03bcM"
        }
      },
      "readouts": [
        "AFM (f_h",
        "lattice parameter",
        "defect density)",
        "laurdan GP (membrane order)",
        "ITC (confirm binding/non-binding of controls to VDAC)",
        "FCS (VDAC diffusion coefficient)",
        "mass spectrometry (drug partitioning into bilayer)"
      ],
      "controls": [
        "5.0-7.0 (uniform)",
        "- bilayer_thickness_change: -0.5-1.0 nm (normal",
        "\u03bc=0.2",
        "\u03c3=0.3)",
        "- partition_coefficient_OMM: 100-10000 (log-uniform)",
        "TESTABILITY: 7",
        "PROTOCOL: Reconstitute VDAC1 (WT and E73Q",
        "T19A mutants) into supported bilayers (OMM-mimetic: POPC/POPE/CL/Chol 48:28:10:14). Treat with CBD (0.5",
        "1",
        "3",
        "5",
        "10",
        "30 \u03bcM)",
        "simvastatin (1",
        "5",
        "10",
        "30 \u03bcM)",
        "vitamin E (logP-matched non-VDAC-binder)",
        "and cholesterol hemisuccinate. Image by AFM",
        "measure membrane order by laurdan GP spectroscopy in parallel GUVs. Timeline: 10-14 weeks.",
        "EXPECTED OUTCOME: CBD at 1-5 \u03bcM (sub-Kd) alters f_h by \u226530%",
        "vitamin E at equi-partitioning concentration produces similar effect",
        "VDAC binding-site mutants show identical f_h shifts as WT",
        "confirming membrane-mediated mechanism. Laurdan GP correlates with f_h across all compounds.",
        "NULL OUTCOME: CBD effects on f_h only appear at >Kd concentrations",
        "VDAC binding-site mutants are resistant to CBD-induced reorganization",
        "logP-matched non-binders have no effect",
        "or laurdan GP changes do not correlate with array changes",
        "indicating direct binding is necessary.",
        "DOSE RANGES: CBD: 0.5",
        "1",
        "3",
        "5",
        "10",
        "30 \u03bcM",
        "Simvastatin: 1",
        "5",
        "10",
        "30 \u03bcM",
        "Vitamin E: 1",
        "5",
        "10",
        "30 \u03bcM",
        "CHS: 1",
        "5",
        "10 \u03bcM",
        "READOUTS: AFM (f_h",
        "lattice parameter",
        "defect density)",
        "laurdan GP (membrane order)",
        "ITC (confirm binding/non-binding of controls to VDAC)",
        "FCS (VDAC diffusion coefficient)",
        "mass spectrometry (drug partitioning into bilayer)",
        "CONTROLS: Vehicle (0.1% DMSO)",
        "protein-free bilayers + drugs (membrane-only effect)",
        "VDAC WT vs mutants at each drug dose",
        "heat-denatured VDAC",
        "cholesterol-only bilayers (no CL)",
        "---",
        "##"
      ]
    },
    {
      "id": "H4",
      "prediction": "IF the honeycomb-to-dispersed transition is the rate-limiting step for apoptosis, THEN: (a) pre-dispersing VDAC arrays (by CL enrichment or cholesterol extraction with M\u03b2CD) will accelerate cytochrome c release by \u22653-fold compared to apoptotic stimulus alone, (b) artificially stabilizing honeycombs (cholesterol loading) will delay cytochrome c release by \u22653-fold even in the presence of BH3-only protein activation, and (c) the time from stimulus to cytochrome c release will correlate with f_h decay kinetics (r\u00b2 > 0.7) rather than with Bax/Bak activation kinetics.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [],
      "testability_score": 5.0,
      "experimental_protocol": "",
      "expected_outcome": "",
      "null_outcome": "",
      "dose_ranges": {},
      "readouts": [],
      "controls": []
    }
  ],
  "n_hypotheses": 4,
  "total_calls": 1,
  "latency_s": 57.75
}